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Background: Although patients with systemic lupus erythematosus (SLE) may experience various gastrointestinal
disorders, SLE and Crohn’s disease (CD) rarely coexist. The diseases may have gastrointestinal (GI) manifestations,
laboratory results, and radiographic findings that appear similar and consequently differentiating between GI
involvement in CD and in SLE may be difficult. We present the case of a patient with SLE and CD who developed
continuous GI bleeding and diarrhea that was initially treated as SLE-related colitis to little effect.
Case presentation: A 55-year-old Japanese woman with systemic lupus erythematosus (SLE) developed
continuous gastrointestinal bleeding and diarrhea since the patient was aged 30 years that was initially treated as
SLE-related colitis. Although a longitudinal ulcer and aphthous ulcers in the colon were observed every
examination, biopsy showed only mild inflammation and revealed neither granuloma nor crypt abscess. The patient
underwent surgery for anal fistulas twice at 50 and 54 years of age and her symptoms were atypical of lupus
enteritis. Colonoscopy was performed again when the patient was 55 years of age because we suspected she had
some type of inflammatory bowel disease (IBD). Cobblestone-like inflammatory polyps and many longitudinal ulcers
were detected between the descending colon and the cecum. Macroscopic examination strongly suggested CD.
Histopathological examination revealed non-caseating granuloma and no evidence of vasculitis, consistent with CD.
Introduction of infliximab dramatically relieved the patient’s melena and abdominal symptoms.
Conclusion: Diagnostic criteria for CD and SLE overlap, making them difficult to diagnose correctly. It is important
to consider CD for patients who have SLE with gastrointestinal manifestations. The pathology of lupus enteritis
should be clarified through the accumulation of cases of SLE combined with CD.
Keywords: Systemic lupus erythematosus (SLE), Crohn’s disease (CD), Longitudinal ulcer, Aphthous ulcers,
Cobblestone-like inflammatory polyps, Non-caseating granuloma, Vasculitis, InfliximabBackground
Systemic lupus erythematosus (SLE) and Crohn’s disease
(CD) are multisystem diseases characterized by wide-
spread tissue damage [1]. The diseases may have gastro-
intestinal (GI) manifestations, laboratory results, and
radiographic findings that appear similar and conse-
quently differentiating between GI involvement in CD
and in SLE may be difficult. There are, in fact, few* Correspondence: hiroyuki_yjp2005@yahoo.co.jp
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distribution, and reproduction in any mediumreports suggesting an association between these diseases
[2-8].
We present the case of a patient with SLE and CD
who developed continuous GI bleeding and diarrhea that
was initially treated as SLE-related colitis to little effect.Case presentation
A 55-year-old woman developed rash and arthralgia
when she was 19 years old. Her physician at the time
diagnosed her illness as SLE because of positive antinuc-
lear antibody (ANA) and anti-double-stranded (dsDNA)
antibody results and began treatment with 30 mg/daytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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10 mg/day. Abdominal pain accompanied by diarrhea
began to occur intermittently when the patient was aged
30 years. She developed fever at the age of 31 years after
swimming in the sea and was admitted to our depart-
ment for treatment and close examination of her chronic
diarrhea. She had a high titer of dsDNA antibody, a
positive result for ANA, polyarthritis, rash, and photo-
sensitivity; therefore, we confirmed the diagnosis of SLE
using the American Rheumatism Association criteria.
Although colonoscopy revealed a linear ulcer, no granu-
loma was detected by biopsy. Due to melena and ab-
dominal pain, she again underwent colonoscopy when
she was 32 and 33 years of age. Although a longitudinal
ulcer in the descending colon (D/C) and aphthous ulcers
in the transverse colon (T/C) and the ascending colon
(A/C) were observed during each examination, biopsy
showed only mild inflammation and revealed neither
granuloma nor crypt abscess. Her PSL dose was
increased to 60 mg/day during each of these hospital vis-
its, because her symptoms were assumed to result from
exacerbation of lupus enteritis. However, remission was
not achieved. GI symptoms were exacerbated whenever
the PSL dose was reduced to ≤15 mg/day. Colonoscopy
performed because of diarrhea when the patient was 39
and 49 years old revealed longitudinal ulcers in D/C and
ulcerative lesions extended over a wide area from the
sigmoid colon to the cecum, no significant finding was
obtained by biopsy. The patient was prescribed immu-
nosuppressants, such as azathioprine (AZA), metho-
trexate (MTX), or tacrolimus (TAC) in addition to PSL
10–20 mg/day and salazosulfapyridine (SASP) 3 g/day at
an outpatient unit of the hospital. However, the patient
repeatedly had melena, positive for immunological fecal
occult blood, and positive for inflammatory responses.
The patient underwent surgery for anal fistulas twice at
50 and 54 years of age and her symptoms were atypicalFigure 1 Findings of colonoscopy and colon biopsy specimens. (A) M
inflammatory polyps and many longitudinal ulcers in the descending colon
eosin, ×100) with noncaseating granuloma and no evidence of vasculitis.of lupus enteritis. Colonoscopy was performed again
when the patient was 55 years of age because we sus-
pected she had some type of inflammatory bowel disease
(IBD). Cobblestone-like inflammatory polyps and many
longitudinal ulcers were detected between the descend-
ing colon and the cecum (Figure 1A). Macroscopic
examination strongly suggested CD. Histopathological
examination revealed non-caseating granuloma and no
evidence of vasculitis (Figure 1B), consistent with CD.
On November 9, 2009, the patient was hospitalized to
begin infliximab treatment for CD at 55 years of age.
Hemoglobin (Hb) was 10.9 g/dl (normocytic), white
blood cell count was 9.44 × 103/ml (neutrophilic leu-
kocytes: 90.8%, lymphocytes: 7.4%), and platelets were
4 × 105/μl. Serum blood urea nitrogen (BUN) was
18.7 mg/dl and creatinine (Cre) was 0.75 mg/dl, with
normal electrolytes, glucose, and liver function tests. Pro-
thrombin time (PT), partial thromboplastin time (PTT),
fibrinogen, and D-dimers were normal. C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate were 1.19
mg/dl and 48 mm/h, respectively. Other laboratory tests
indicated the presence of ANA, anti-SS-A antibodies,
normal complement levels, and a high titer of anticardio-
lipin (aCL)-β2GPI (68.9 U/ml). The tests for anti-dsDNA
antibodies had become negative because of the admi-
nistration of steroid. Urinalysis was normal and stool
cultures did not reveal any infection. Her stools were
positive for occult blood.
Introduction of infliximab dramatically relieved the
patient’s melena and abdominal symptoms. Infliximab
was administered at a dose of 5 mg/kg body weight (340
mg) at weeks 0, 2, and 6, and then every 8 weeks there-
after. Regarding inflammatory responses after 1 month
of infliximab administration, the CRP level normalized
from 1.19 mg/dl to 0.06 mg/dl, and the erythrocyte sedi-
mentation rate (ESR) from 48 mm/hr to 14 mm/hr. The
Harvey-Bradshaw index (HBI) score was also reducedacroscopic findings of colonoscopy with cobble-stone-like
. (B) Histopathological findings of specimens in A (hematoxylin and
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matory response and negative test results for fecal
occult blood. Ultimately, the PSL dose was reduced to
5 mg/day, and both MTX and TAC were tapered to dis-
continuation. As of May 2012, remission is maintained
with infliximab, 5 mg/day PSL, and 3 g/day SASP. How-
ever, the aCL-β2GPI antibody titers remain high.
Discussion
Although patients with SLE may experience various GI
disorders, SLE and CD rarely coexist [2-8]. Table 1 lists
reports of the combination of SLE and CD. Except in
Case 4, CD developed a mean of 12.0±12.2 years after
the onset of SLE symptoms. In the case reported here,
the patient developed regular CD more than 36 years
after onset of SLE. All cases were positive for anti-
dsDNA antibodies or anti-DNA antibodies. Polyarthritis





























































M,male; F, female; ANA, antinuclear antibody; Anti-DNA, antinative deoxyribonucleic
antinative double-stranded antinative deoxyribonucleic acid antibody.The frequency of peripheral arthritis among CD patients
is 1–22% and symptoms similar to those of collagen dis-
ease may develop [9]. Therefore, a causal relationship
between SLE and CD cannot be excluded.
SLE is a multisystemic disease; therefore, patients fre-
quently present with GI disorders that may be clinically
similar to CD. However, there are some differences [4].
Compared to SLE, CD presents more frequently as diar-
rhea, abdominal pain, and anal lesions. All seven
patients described in Table 1 experienced diarrhea,
whereas five experienced abdominal pain, and two had
anal lesions. CD has greater ileal involvement with a
more segmented distribution than SLE, and radiographs
show deep ulcers, fissures, and a cobblestone appearance
or fistula formation as well as the macroscopic colonos-
copy findings. Plain film radiographs of SLE-related mes-
enteric vasculitis usually show nonspecific indications of
disease, such as segmental bowel dilatation in a thumb-ng Crohn disease
Colonoscopy
findings







































































acid antibody; mPSL, methylprednisolone; N/A, not available; Anti-dsDNA,
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http://www.biomedcentral.com/1471-230X/12/174print pattern and an air–fluid level. CT scans reveal the
characteristic features of IBD (e.g., a double halo sign
and comb-like appearance of the supplying vessels).
Angiography of the mesenteric arteries may also provide
evidence of vasculitis.
The most common pathological lesions in the GI tract
of patients with SLE are chronic, nonspecific mucosal
inflammation and ischemic changes due to vascular
lesions. However, vasculitis was not confirmed in any of
the cases presented in Table 1. Therefore, the abdominal
symptoms experienced by patients with both SLE and
CD can be attributed to CD alone.
Additionally, perforation rarely occurs in IBD, but is
often observed in lupus enteritis, and may be helpful in
differential diagnosis [10]. GI lesions associated with
SLE are roughly classified into two types: (1) those asso-
ciated with vasculitis and that frequently cause perfor-
ation; and (2) nonspecific ulcerative or granulomatous
colitis [11]. The latter indicate that CD is complicating
SLE. Therefore, when encountering steroid-resistant
SLE-associated enteritis with the typical findings of CD,
such as macroscopic findings of cobblestone-like inflam-
matory polyps, histopathological findings of noncaseat-
ing granuloma, and the presence of discontinuous
longitudinal ulcers and aphthous ulcers in the colon, a
diagnosis of CD should be considered in the differential,
and anti-TNF-α therapy should be kept in mind.
Patients with IBD that is treated with sulfasalazine
can, in rare cases, develop drug-induced lupus syndrome
[12]. Drug-induced lupus syndrome is associated with
negative ANA laboratory tests and hypocomplemente-
mia. The patient described here was positive for ANA
and anti-dsDNA antibody before the administration of
SASP when she was 19 and 31 years old; therefore,
drug-induced lupus syndrome was unlikely.
In early CD lesions, such as aphthous ulcers associated
with noncaseating granuloma, macrophagic epithelioid
cells aggregate in response to antigens from food and en-
teric bacteria that have invaded the intestinal mucosa.
These macrophagic cells produce proinflammatory cyto-
kines, such as interleukin-6 and tumor necrosis factor
(TNF)-α, which are considered to be important for the de-
velopment of CD. It is for this reason that CD is classified
as an autoimmune disease [13]. In the case described here,
administration of steroids in early-stage SLE might have
delayed the onset of obvious lower GI CD lesions.
The overall prevalence of aCL antibodies among CD
patients is approximately 22% [14]. Although the patient
was strongly positive for aCL antibodies, coagulation
factor levels were always within the normal range. More-
over, the patient had no history of thrombosis. Thus,
concomitant antiphospholipid syndrome is unlikely.
Glucocorticosteroid is an effective treatment for CD,
and can be used to treat severe cases or disease thatdoes not respond well to mesalazine therapy. However,
longterm treatment with glucocorticosteroids should be
avoided. In case of steroid dependency or steroid re-
fractory TNF-alpha blockers are an effective treatment
to induce and maintain remission [15]. In the case
described herein, CD activity was not controlled by
high-dose PSL therapy or by moderate doses of ster-
oids and SASP. However, a complete response was
achieved with anti-TNF-α therapy. TNF-α inhibitors
have been reported to cause drug-induced lupus, as
well as rashes and arthritis [16]. Fortunately, in this
case, SLE symptoms did not worsen. There are, how-
ever, occasional reports describing the efficacy of anti-
TNF-α therapy for SLE. It has also been reported that,
despite levels of antibodies to ds-DNA and cardiolipin
being increased, anti-TNF-α therapy did not exacerbate
SLE itself but rather achieved a reduction in disease
activity and relief of refractory arthritis, nephritis, etc.
[17]. TNF-α exerts both deleterious tissue damaging
effects mainly through its pro-inflammatory activities
and beneficial activities by dampening aggressive auto-
immune responses. SLE is a disease with autoimmune
disturbance and inflammatory damage, so blocking
TNF-α in this autoimmune-prone chronic inflamma-
tory disease may lead to different outcomes, depending
on timing and duration of treatment[18]. Thus, inflixi-
mab may also be effective for gastrointestinal symp-
toms associated with SLE.
Conclusion
In conclusion, the diagnostic criteria for CD and SLE
overlap, making them difficult to diagnose correctly. It is
important to consider the possibility of CD in patients
who have SLE with GI manifestations. The status of CD
as an autoimmune disease is becoming clear and the
pathology of lupus enteritis should be clarified through
the accumulation of cases of SLE combined with CD.
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